Raymond E. Moellering
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Raymond E. Moellering has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin D. Stein
Sandra and Edward Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, New York
47 shared publications - John S. Coukos
Department of Chemis-try, University of Chicago, Chicago, Illinois
47 shared publications - David Wu
Sandra and Edward Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, New York
46 shared publications - Eric Edison Gardner
Meyer Cancer Center, Weill Cornell Medicine
45 shared publications - Harold Varmus
Meyer Cancer Center, Weill Cornell Medicine
45 shared publications - Jae Won Chang
Department of Pharmacology and Chemical Biology Emory University Atlanta Georgia USA
45 shared publications
Latest Publications
- 16 March 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (12) , 12641-12654
Molecular Dynamics-Guided Design and Chemoproteomic Profiling of Covalent Kinase Activity Probes
Covalent small molecule probes can be powerful tools to interrogate protein activity state in native cellular environments. The design of familywide activity probes requires an understanding of the molecular sources of conserved and target-specific small molecule targeting across protein family members. Here, we developed and applied a multifaceted docking and molecular dynamics (MD) simulation pipeline to design cell-permeable covalent kinase activity probes from a set of hinge-binding pharmacophores. This computationally-guided approach yielded a series of cell-active indazole sulfonylfluorides that target a conserved catalytic lysine in active protein kinases. Chemoproteomic profiling of a lead probe, K60P, confirmed engagement of more than 100 unique native kinases across several cancer cell lines. Competitive profiling identified kinases as the predominant class of specific targets for K60P but also highlighted significant nonkinase targets for K60P and the established covalent kinase probe, XO44, underscoring the utility of native kinase profiling in situ to identify relevant targets of small molecule kinase inhibitors in cells. Dose-, time- and site-specific proteomic mapping with a known target kinase, ABL1, coupled with a Bayesian Metropolis Monte Carlo (BMMC) kinetic modeling method showed that key descriptors of covalent probe efficiency could be predicted with straightforward dose- and time-dependent covalent engagement studies and highlighted kinact/KI as a key variable to optimize for specific and broad kinase engagement. Finally, focused molecular dynamics simulations revealed that K60P, as well as the comparator probe XO44, preferentially engage with target kinases in their active, DFG-in conformations, which is driven by increasing population of reaction-ready small molecule conformation. These results together establish a computational and kinetic modeling framework for designing covalent activity probes and highlight the balance of target selectivity and kinetic efficiency as a key factor in determining their proteome-wide reactivity.
- 16 March 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (12) , 12641-12654
Molecular Dynamics-Guided Design and Chemoproteomic Profiling of Covalent Kinase Activity Probes
Covalent small molecule probes can be powerful tools to interrogate protein activity state in native cellular environments. The design of familywide activity probes requires an understanding of the molecular sources of conserved and target-specific small molecule targeting across protein family members. Here, we developed and applied a multifaceted docking and molecular dynamics (MD) simulation pipeline to design cell-permeable covalent kinase activity probes from a set of hinge-binding pharmacophores. This computationally-guided approach yielded a series of cell-active indazole sulfonylfluorides that target a conserved catalytic lysine in active protein kinases. Chemoproteomic profiling of a lead probe, K60P, confirmed engagement of more than 100 unique native kinases across several cancer cell lines. Competitive profiling identified kinases as the predominant class of specific targets for K60P but also highlighted significant nonkinase targets for K60P and the established covalent kinase probe, XO44, underscoring the utility of native kinase profiling in situ to identify relevant targets of small molecule kinase inhibitors in cells. Dose-, time- and site-specific proteomic mapping with a known target kinase, ABL1, coupled with a Bayesian Metropolis Monte Carlo (BMMC) kinetic modeling method showed that key descriptors of covalent probe efficiency could be predicted with straightforward dose- and time-dependent covalent engagement studies and highlighted kinact/KI as a key variable to optimize for specific and broad kinase engagement. Finally, focused molecular dynamics simulations revealed that K60P, as well as the comparator probe XO44, preferentially engage with target kinases in their active, DFG-in conformations, which is driven by increasing population of reaction-ready small molecule conformation. These results together establish a computational and kinetic modeling framework for designing covalent activity probes and highlight the balance of target selectivity and kinetic efficiency as a key factor in determining their proteome-wide reactivity.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S2. Phosphorylation of human TPI1 is LKB1-dependent.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S2. Phosphorylation of human TPI1 is LKB1-dependent.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S1. Differential co-occurrence and effects of KRAS, TP53 and LKB1 mutations on human and mouse LUADs.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S1. Differential co-occurrence and effects of KRAS, TP53 and LKB1 mutations on human and mouse LUADs.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S5. LKB1 regulates the multimeric state of hTPI1 but not mTpi1 and substitution of Cys in hTPI1 causes formation of a covalent TPI1 dimer.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S5. LKB1 regulates the multimeric state of hTPI1 but not mTpi1 and substitution of Cys in hTPI1 causes formation of a covalent TPI1 dimer.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S3. TPI1 phosphorylation regulates triose phosphate levels and metabolic flux.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S3. TPI1 phosphorylation regulates triose phosphate levels and metabolic flux.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S6. TPI1 allelic variants effects central carbon metabolic flux.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S6. TPI1 allelic variants effects central carbon metabolic flux.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S4. Members of the salt Inducible kinase family phosphorylate TPI1.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S4. Members of the salt Inducible kinase family phosphorylate TPI1.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S8. Tpi1 inactivation in KL autochthonous tumor model alters histology and pathology.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S8. Tpi1 inactivation in KL autochthonous tumor model alters histology and pathology.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S7. Tpi1 is required for tumor growth in KP and KPL LUAD models.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S7. Tpi1 is required for tumor growth in KP and KPL LUAD models.
- Open Access
- 27 November 2025
- Published by Wiley in International Journal of Cancer
- Vol. 158 (7) , 1927-1940
Reprogramming SREBP1 ‐dependent lipogenesis and inflammation in high‐risk breast with licochalcone A: A novel path to cancer prevention
Anti‐estrogens have had a limited impact on breast cancer (BC) prevention. Novel agents with better tolerability, and efficacy beyond estrogen receptor (ER) positive BC are needed. We studied licochalcone A (LicA) for ER‐agnostic BC prevention. We demonstrated that LicA significantly reduced proliferation in seven human breast cell lines and suppressed ER+ and ER− xenograft tumors in mice. We confirmed these observations ex vivo in the contralateral unaffected breast (CUB) of women with unilateral sporadic BC, and BC cell lines using RNA sequencing, metabolism flux modeling, confirmatory NanoString nCounter metabolic pathway panel analysis in independent sets of specimens, proteomics, and western blots. We found that LicA targets sterol regulatory element binding protein 1 (SREBP1) with subsequent metabolic‐inflammatory changes, lowering spatiotemporally resolved cholesterol levels inside malignant cells to the levels in normal mammary cells. Mechanistically, in CUBs we observed that LicA downregulated PI3K‐AKT‐SREBP1‐dependent lipogenesis, NF‐kB‐dependent inflammation, and de novo nucleotide biosynthesis, stalling proliferation. Studies in cell lines showed suppression of PI3K and AKT phosphorylation, SREBP1 protein expression, and the SREBP1‐dependent enzymes such as ACAT2, ACLY, FASN, SCD, consistent with reduced NEDD8 required for SREBP1 stabilization. We found a significant reduction in NF‐kB expression, its nuclear translocation mediator karyopherin β 1, and prostaglandin E2 synthesis. We demonstrated a reduction in PRPS1‐catalyzed de novo nucleotide biosynthesis, and downregulation of proliferative markers MKI67, RRM2, and the survival marker BCL2. LicA reduces pro‐tumorigenic aberrations in lipid homeostasis and inflammation through SREBP1. It is a promising non‐endocrine candidate for BC prevention. Future studies in immunocompetent BC prevention models are warranted.
- 27 November 2025
- Published by Wiley in International Journal of Cancer
- Vol. 158 (7) , 1927-1940
Open AccessReprogramming SREBP1 ‐dependent lipogenesis and inflammation in high‐risk breast with licochalcone A: A novel path to cancer prevention
Anti‐estrogens have had a limited impact on breast cancer (BC) prevention. Novel agents with better tolerability, and efficacy beyond estrogen receptor (ER) positive BC are needed. We studied licochalcone A (LicA) for ER‐agnostic BC prevention. We demonstrated that LicA significantly reduced proliferation in seven human breast cell lines and suppressed ER+ and ER− xenograft tumors in mice. We confirmed these observations ex vivo in the contralateral unaffected breast (CUB) of women with unilateral sporadic BC, and BC cell lines using RNA sequencing, metabolism flux modeling, confirmatory NanoString nCounter metabolic pathway panel analysis in independent sets of specimens, proteomics, and western blots. We found that LicA targets sterol regulatory element binding protein 1 (SREBP1) with subsequent metabolic‐inflammatory changes, lowering spatiotemporally resolved cholesterol levels inside malignant cells to the levels in normal mammary cells. Mechanistically, in CUBs we observed that LicA downregulated PI3K‐AKT‐SREBP1‐dependent lipogenesis, NF‐kB‐dependent inflammation, and de novo nucleotide biosynthesis, stalling proliferation. Studies in cell lines showed suppression of PI3K and AKT phosphorylation, SREBP1 protein expression, and the SREBP1‐dependent enzymes such as ACAT2, ACLY, FASN, SCD, consistent with reduced NEDD8 required for SREBP1 stabilization. We found a significant reduction in NF‐kB expression, its nuclear translocation mediator karyopherin β 1, and prostaglandin E2 synthesis. We demonstrated a reduction in PRPS1‐catalyzed de novo nucleotide biosynthesis, and downregulation of proliferative markers MKI67, RRM2, and the survival marker BCL2. LicA reduces pro‐tumorigenic aberrations in lipid homeostasis and inflammation through SREBP1. It is a promising non‐endocrine candidate for BC prevention. Future studies in immunocompetent BC prevention models are warranted.